

**From:** Leonhart, Michele M.  
**Sent:** Fri, 26 Mar 2010 09:18:48 -0400  
**To:** Rannazzisi, Joseph T.;Boggs, Gary;Rannazzisi, Joseph T.;Boggs, Gary  
**Subject:** Fw: Folow-Up to our Meeting on Prescription Drug Diversion and Overdose

Let me know your thoughts. Anything incorrect?

---

**From:** McLellan, Andrew T. (b)(6)  
**To:** Koh, Howard (HHS/OPHS) (b)(6); Leonhart, Michele M.;  
joshua.sharfstein@fda.hhs.gov <joshua.sharfstein@fda.hhs.gov>; Thomas.Frieden@cdc.gov  
<Thomas.Frieden@cdc.gov>  
**Cc:** Moorin, Arnold R. (b)(6); LaBelle, Regina M.  
(b)(6); Quinn, Timothy (b)(6); Humphreys,  
Keith N. (b)(6); Kerlikowske, Richard G.  
(b)(6); Sivilli, June S. (b)(6)  
**Sent:** Fri Mar 26 09:15:24 2010  
**Subject:** Folow-Up to our Meeting on Prescription Drug Diversion and Overdose

Colleagues - This will review the results from the first "principals meeting" (March 18, 2010 – at ONDCP) on the issue of preventing prescription drug diversion and prescription drug overdoses.

(b)(5)

In that context please suggest ways in which ONDCP could be helpful to this effort.

Attendance

Drug Enforcement Agency –Michelle Leonhart & Joe Ranizizi  
Food and Drug Administration – Janet Woodcock & Josh Sharfstein  
Centers for Disease Control – Tom Frieden (Not able to attend)  
Health and Human Services (Public Health) – Howard Koh (participating by phone)  
Office of National Drug Control Policy – Gil Kerlikowske, Regina LaBelle, Tom McLellan, Arnie Moorin, Keith Humphreys

Background Work of the Agencies Represented

(b)(5)

(b)(5)

Differentiating the Problem and Describing Solutions

(b)(5)

Problems With Existing Agency Controls – At the meeting all agencies reported one of more problems with existing efforts to reduce prescription drug diversion and overdose:

(b)(5)

(b)(5);(b)(7)(E)

(b)(5)

(b)(5)

A. Thomas McLellan  
Deputy Director and Chief Scientist  
White House Office of National Drug Control  
Washington, DC 20530

(b)(6)